IRIDEX Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 30, 2023 (52 weeks), compared with fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing. IRIDEX develops and sells ophthalmic laser systems, delivery devices, consumable probes, and related services for glaucoma and retinal diseases.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $51.9 million | $57.0 million |
| Gross profit / margin | $21.8 million / 42.0% | $25.4 million / 44.5% |
| Operating expenses | $31.8 million | $32.9 million |
| Operating loss | $10.0 million | $7.5 million |
| Net loss | $9.6 million ($0.59 per share) | $7.5 million ($0.47 per share) |
| Cash used in operating activities | $6.7 million | $9.5 million |
| Cash and cash equivalents at year-end | $7.0 million | $13.9 million |
| Working capital at year-end | $14.5 million | $23.3 million |
IRIDEX had total assets of $34.4 million, total liabilities of $24.9 million, and stockholders’ equity of $9.5 million at year-end. The balance sheet reports no borrowing balance; its secured revolving facility of up to $8.0 million with Silicon Valley Bank expired December 1, 2023, and the company was negotiating renewal and new terms. Management said existing cash should meet anticipated needs for at least 12 months, while also expecting continued operating losses and negative operating cash flows. No numerical forward revenue or profitability guidance is provided.
Changes versus FY2022
- Revenue declined $5.1 million, or 9.0%. Retina revenue fell 7.0%, Cyclo G6 revenue fell 8.4%, and “Other” revenue fell 15.6%.
- Gross margin fell 2.5 percentage points to 42.0%; gross profit decreased 14.0%. The filing attributes margin pressure to lower overhead absorption, with FY2022 also benefiting from a more favorable product mix.
- Net loss widened by approximately $2.0 million despite lower operating expenses. Lower sales and gross profit, plus higher general and administrative expenses, contributed to the deterioration.
- Operating cash use improved by $2.8 million, partly as inventory and supply-chain conditions normalized, but year-end cash decreased by $6.9 million.
- General and administrative expenses rose 15.8% to $8.7 million, including higher personnel costs, separation costs, and legal expenses. R&D and sales and marketing expenses declined.
Outlook, risks, and notable items
- Management reported that customers extended capital-equipment purchasing decisions amid inflation, high interest rates, recession concerns, and currency effects; it also noted demand softness associated with the strong U.S. dollar. The duration and impact of these conditions remain uncertain.
- Topcon is a significant distributor and related party, holding 10.1% of IRIDEX’s voting interest. Topcon-related revenue was $14.3 million, approximately 30% of FY2023 revenue; amounts due from Topcon were $2.9 million at year-end. The company also purchases certain materials from Topcon.
- International sales represented 49.8% of FY2023 revenue. Risks include distributor dependence, foreign-exchange effects, regulatory requirements, reimbursement changes, and geopolitical or trade disruptions.
- IRIDEX relies on third parties, including sole- or limited-source suppliers, for substantially all product components. Manufacturing quality, supply continuity, and demand forecasting could affect deliveries and margins.
- The European MDR transition deadline for the company’s affected products was extended to 2028; IRIDEX said it intends to obtain certification before the applicable deadline. Failure to maintain regulatory clearances or certifications could impair sales.
- The auditor gave an unqualified opinion on the financial statements. Inventory valuation was identified as a critical audit matter, particularly management’s estimates of demand, product life cycles, and excess or obsolete inventory. Inventory was $9.9 million at year-end.
- The company capitalized $1.1 million of cloud-based ERP implementation costs and began amortizing them over five years in 2023. It also reported $940,000 of accrued ERP implementation expenses at year-end.
- Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not attest to internal control effectiveness. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Key facts for investors to verify
- Whether IRIDEX renews or replaces its expired credit facility, and whether management’s 12-month liquidity assessment remains supportable given cash burn and declining cash.
- Subsequent revenue, gross-margin, and cash-flow trends, particularly whether demand and overhead absorption improve.
- Topcon’s ongoing sales contribution, receivable collections, distribution performance, and related-party transactions.
- Inventory quality and reserves, and whether the $9.9 million inventory balance is aligned with demand and product plans.
- Progress toward European MDR certification and continued access to international markets.